In the latest shareholder lawsuit, a pension fund accused executives at Emergent BioSolutions of insider trading. The company, under investigation by Congress, has halted manufacturing of Covid-19 vaccines at its Baltimore factory at regulators’ request.
from NYT > U.S. News https://ift.tt/3xmdCu0
https://ift.tt/eA8V8J
0 Comments